Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

On Tuesday night, millions of Americans watched as former president Donald J. Trump gathered up enough electoral votes needed ...

After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting ...

With Indivior’s stock price in freefall over the past year, one of the company’s top investors is taking leadership to task, ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...